A randomized controlled trial undertaken to test a nurse-led weight management and exercise intervention designed for people with serious mental illness who take second generation antipsychotics

Journal of Advanced Nursing

Volumn 69, Issue 7, 2013, Pages 1539-1548

  Usher, Kim ^a   Park, Tanya ^a   Foster, Kim ^b   Buettner, Petra ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Metabolic syndrome; Nursing; Second generation antipsychotic medications; Serious mental illness; Weight gain

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUSTRALIA; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CURRICULUM; EXERCISE; FEMALE; FOLLOW UP; HUMAN; LIFESTYLE; MALE; MENTAL DISEASE; METABOLIC SYNDROME X; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NURSING; OBESITY; PATIENT EDUCATION; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; CURRICULUM; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE STYLE; MALE; MENTAL DISORDERS; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PATIENT EDUCATION AS TOPIC; QUEENSLAND; WEIGHT LOSS;

EID: 84878664366     PISSN: 03092402     EISSN: 13652648     Source Type: Journal    
DOI: 10.1111/jan.12012     Document Type: Article

References (39)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C. & Weiden P.J. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156, 1686-1696.
2. Alvarez-Jimenez M., Gonzalez-Blanch C., Crespo-Facorro B., Hetrick S., Rodríguez-Sánchez J.M., Pérez-Iglesias R. & Vázquez-Barquero J.L. (2008) Antipsychotic-induced weight gain in chronic and first episode psychotic disorders - a systematic critical reappraisal. CNS Drugs, 22, 547-562.
3. Awad A.G. (1993) Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin, 19, 609-618.
4. Ball M.P., Coons V.B. & Buchanan R.W. (2001) A program for treating Olanzapine-related weight gain. Psychiatric Services 52 (7), 967-969.
5. Bardwell M. & Taylor R. (2009) Schizophrenic disorders. In Psychiatric and Mental Health nursing, 2nd ed (Elder R., Evans K. & Nizette D., eds), Elsevier, New South Wales, pp. 248-266.
6. Brunero S., Lamont S. & Fairbrother G. (2009) Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia. Archives of Psychiatric Nursing 23(3), 261-268.
7. Chen H., Cohen P., Crawford T.N., Kasen S., Guan B. & Gorden K. (2009) Impact of early adolescent psychiatric and personality disorder on long-term physical health: A 20 year longitudinal follow-up study. Psychological Medicine, 39, 865-874.
8. Citrome L., Blonde L. & Damatarca C. (2005) Metabolic issues in patients with severe mental illness. Southern Medical Association 98(7), 714-720.
9. Evans S., Newton R. & Higgins S. (2005) Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomised controlled trial. Australian New Zealand Journal of Psychiatry 39, 479-486.
10. Faulkner G., Cohn T. & Remington G.(2007). Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews (1) Art. No.: CD005148. Doi: 10.1002/14651858.CD005148.pub2.
11. Graham K.A., Gu H., Lieberman J.A., Harp J.B. & Perkins D.O. (2005) Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. American Journal of Psychiatry, 162(9), 1744-1746.
12. International Diabetes Federation (IDF) (2006) The IDF consensus worldwide definition of the Metabolic Syndrome. Retrieved from http://www.idf.org/ on 8 January 2009.
13. John A.P., Koloth R., Dragovic M. & Lim S.C.B. (2009) Prevalence of metabolic syndrome among Australians with severe mental illness. Medical Journal of Australia 190(4), 176-179.
14. Kemp R., Hayward P., Applewhaite G., Everitt B. & David A. (1996) Compliance therapy in psychotic patients: randomised controlled trial. British Medical Journal, 312, 345-349.
15. Kim J.H., Kim S.Y., Ahn Y.M. & Kim Y.S. (2006) Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 30, 301-305.
16. Knowler W.C., Hamman R.F., Edelstein S.L., Barrett-Connor E., Ehrmann D.A., Fowler S.E., Nathan D.M. & Kahn S.E.; Diabetes Prevention Program Research Group (2005) Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54(4), 1150-1156.
17. Kwon J.S., Choi J.S., Bahk W.M., Kim C.Y., Kim C.H., Shin Y.C., Park B.J. & Oh C.G. (2006) Weight management program for treatment-emergent weight gain in olanzapine patients with schizophrenia and schizoaffective disorder: 12 week randomized controlled clinical trial. Journal of Clinical Psychiatry, 67(4), 547-553.
18. Lindenmayer J.P., Khan A., Wance D., Maccabee N., Kaushik S. & Kaushik S. (2009) Outcome evaluation of a structured educational wellness program in patients with severe mental illness. Journal of Clinical Psychiatry 70(10), 1385-1396.
19. Littrell K.H., Hilligoss N.M., Kirshner C.D., Petty R.G. & Johnson C.G. (2003) The effects of an educational intervention on antipsychotic-induced weight gain. Journal of Nursing Scholarship 35, 237-241.
20. McCloughen A. & Foster K. (2011) Weight gain associated with taking psychotropic medication: an integrative review. International Journal of Mental Health Nursing 20, 202-222.
21. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Stroup T.S. & Lieberman J.A. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness(CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80, 19-32.
22. Melamed Y., Stein-Reisner O., Gelkopf M., Levi G., Sivan T., Illevici G., Rosenberg R., Weizman A. & Bleich A. (2008) Multimodal weight control intervention for people with persistent mental disorders. Psychiatric Rehabilitation Journal, 31(3), 194-200.
23. Morrison P.A., Gaskill D., Meehan T., Lunney P., Lawrence G. & Collings P. (2000) The use of the Liverpool University neuroleptic side-effect rating scale (LUNSERS) in clinical practice. Australian and New Zealand Journal of Mental Health Nursing, 9(4), 166-176.
24. Park T., Usher K. & Foster K. (2011) Description of a healthy lifestyle intervention for people with schizophrenia taking second generation antipsychotics. International Journal of Mental Health Nursing 20(6), 428-437.
25. Poulin M.J., Chaput J.P., Simard V., V P., Bernier J., Gauthier Y., Lanctot G., Saindon J., Vincent A., Gagnon S. & Tremblay A. (2007) Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Australian and New Zealand Journal of Psychiatry 41, 980-989.
26. Richardson C.R., Avripas S.A., Neal D.L. & Marcus S.M. (2005) Increasing lifestyle physical activity in patients with depression or other serious mental illness. Journal of Psychiatric Practice, 11 (6), 379-388.
27. Robson D. & Gray R. (2007) Serious mental Illness and physical health problems: A discussion paper. International Journal of Nursing Studies, 44(3), 457-466.
28. Schneider Z., Whitehead D. & Elliott D. (2007) Nursing & Midwifery Research: Methods and Appraisal for Evidence Based Practice, 3rd edn. Elsevier, Sydney.
29. Skouroliakou M., Giannopoulou I., Kostara C. & Hannon J.C. (2009) Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine. Nutrition, 25, 729-735.
30. Smith S., Yeomans D., Bushe C.J., Eriksson C., Harrison T., Holmes R., Mynors-Wallis L., Oatway H. & Sullivan G. (2007) A well-being programme in severe mental illness. Reducing the risk for physical ill-health: a post-programme service evaluation at 2 years. European Psychiatry 22(7), 413-418.
31. Tirupati S. & Chua L.E. (2007) Obestiy and metabolic syndrome in a psychiatric rehabilitation service. Australian and New Zealand Journal of Psychiatry 42(2), 606-610.
32. Tschoner A., Engl J., Laimer M., Kaser S., Rettenbacher M., Fleischhacker W.W., Patsch J.R. & Ebenbichler C.F., (2007) Metabolic side effects of antipsychotic medication. International Journal of Clinical Practice 61(8), 1356-1370.
33. Turner-Bowker D., Bartley P. & Ware J. (2002) SF-36Ò Health Survey & "SF" bibliography, 3rd ed, Quality Metric Incorporated, Lincoln.
34. Usher K., Foster K. & Bullock S. (2009) Psychopharmacology for Health Professionals. Elsevier, Chatswood, NSW, Australia.
35. Vreeland B., Minsky S., Menza M., Radler D.R., Roemheld-Hamm B. & Stern R. (2003) A program for managing weight gain associated with atypical antipsychotics. Pyschiatric Services 54 (8), 1155-1157.
36. Wand T. & Murray L. (2008) Let's get physical. International Journal of Mental Health Nursing 17, 363-369.
37. Ware J.E., Kosinski M. & Dewey J.E. (2002) How to score version 2 of the SF-36 Health survey. QualityMetric Inc, Lincoln, RI.
38. Weber M. & Wyne K. (2006) A cognitive/behavioural group intervention for weight loss in patients treated with atypical antipsychotics. Schizophrenia Research 83, 95-101.
39. Wu R-R., Zhao J-P., Jin H., Shao P., Fang M-S., Guo X-F., He Y-Q., Liu Y-Q., Chen J-D. & Li L-H. (2008) Lifestyle intervention and Metformin for treatment of antipsychoticinduced weight gain. Journal of American Medical Association, 299(2), 185-193